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0.87-1.07, p < 0.606). ConClusions: The needs of the developmentally disabled 
individuals are somewhat different than the needs of individuals without disabili-
ties. Policy recommendations should focus on increasing the number of outpatient 
centers as well as primary caregivers who can understand the disease management 
needs of the patient and accordingly collaborate with other specialized health care 
professionals to enhance the overall quality of care for the patient.
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objeCtives: Earlier studies (Zang et al. 2008) in the field of diabetes identified that 
there is a significant relationship between the time before diagnosis and health 
insurance in the United States. Another study (Zang et al. 2012) among US habit-
ants showed that the type of insurance is also significantly related to poor glyce-
mic control. Our study aimed to identify whether there is a relationship between 
socio-demographics (e.g. insurance type) and Health Related Quality of Life (HRQoL) 
among diabetes patients in the United States. Specifically, our study aimed to evalu-
ate the relationship between HRQoL and age, gender, household income, employ-
ment and insurance type. Methods: A cross-sectional survey of diabetes patients 
(n = 1480) living in the United States. Each patient completed a comprehensive ques-
tionnaire, which included the EQ-5D-5L instrument and accompanying VAS. In addi-
tion to the EQ-5D-5L instruments patients were also asked a series of questions to 
identify their socio-demographic background. By means of logistic linear regression 
modeling the health utility scores derived from the EQ-5D-5L instrument are linked 
to the socio-demographic background of the diabetes patients. Results: The tested 
socio-demographics are significantly related to HRQoL (p < 0,0001). Yet, together 
they explained only 10% of the variation in HRQoL score (R² = 0,10). Insurance by 
Medicaid (β -value: -0,16) and employment (β -value: 0,13) were both significantly 
related to HRQoL (p < 0,0001). Household income (p = 0,253), insurance by Medicare 
(p = 0,16), gender (p = 0,12), level of education (p= 0,04), and age (p= 0,013) all were 
less significantly related to HRQoL. ConClusions: The study reconfirms the rela-
tionship between insurance, employment and health outcomes among diabetes 
patients in the United States. Previous studies showed that these affect the access 
to care and the diabetes management, but these are also likely to influence health 
outcomes in terms of HRQoL.
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objeCtives: Treatment satisfaction is an important factor of quality of care, espe-
cially in treating chronic diseases such as DM. The goal of study was to test use-
fulness of the new tool for assessing treatment satisfaction – Patient Treatment 
Satisfaction Questionnaire (PTSQ) in the population of type 2 DM (T2DM) 
patients. Methods: 500 patients with T2DM on different basal-bolus insulin treat-
ment were included in the study: mean age 61.8; male/female – 122/378; DM dura-
tion – 12.8 years; mean duration of insulin therapy – 5.1±4.3 yrs. 64.4% of patients 
exhibited hypoglycemia. PTSQ consists of five numerical rating scales, scored from 0 
(extremely dissatisfied) to 10 (extremely satisfied): 4 core items – general treatment 
satisfaction, treatment effectiveness, convenience and coping, and one additional 
item – side effects burden. Patients filled out the PTSQ and SF-36 during routine 
check-up. The construct validity of the PTSQ was proved by “known-group” com-
parison and correlations with SF-36 subscales. Cronbach alpha was used to estimate 
internal consistency. Results: Items of the PTSQ were easy for the patients to read 
and understand. Patients needed 3-5 min to answer it, usually without assistance. 
The proportion of missing values for all items was less than 2.5%. The instrument 
found high acceptance reflected by only 1% of refusals. Patients with severe hypogly-
cemia were less satisfied with treatment than those without hypoglycemia (p< 0.05). 
Patient-reported treatment effectiveness and convenience were lower in patients 
on human NPH insulin than in those on ultrashort analogues of insulin in combina-
tion with long operating basal insulin (p< 0.05). Reliability of the tool appeared to be 
satisfactory: Chronbach’s alpha coefficient = 0.91. As a whole, treatment satisfaction 
was high-rated by patients (84.4%); 1.4% of patients were extremely dissatisfied with 
ongoing insulin therapy. ConClusions: Thus, the PTSQ is a useful instrument to 
evaluate treatment satisfaction in the population of DM patients.
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objeCtives: Only a few studies have reported how Body Mass Index (BMI) relates 
to the Health-Related Quality of Life (HRQoL) of diabetic patients in the US, and 
results of these studies are mixed. This study assessed the relationship between 
BMI and HRQoL using the US 2006-2010 Medical Expenditure Panel Survey (MEPS) 
database. Methods: Eligible patients were ≥ 18 years, with a diabetes diagnosis 
(CCC-250) and on at least one oral antidiabetic medication. HRQoL was calcu-
lated using SF-12 scores: 1) Physical Component Summary [PCS-12] and 2) Mental 
Component Summary [MCS-12]. In the general population, these scores have a 
mean of 50 and a standard deviation of 10, with higher scores correlating with 
better HRQoL (physical and mental health respectively). The main independent 
variable was BMI, categorized as normal weight BMI: 18.0-24.9; overweight BMI: 
25.0-29.9; obese BMI: 30.0-40.0; and morbidly obese BMI: > 40.0 kg/m2. Multivariate 
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objeCtives: To investigate the marginal impact of depression on self-reported men-
tal health status in adults with diabetes mellitus in the United States. Methods: 
We pooled years 2009 and 2011 from the Medical Expenditure Panel Survey (MEPS) 
to create a retrospective cohort of adults diagnosed with diabetes, and those with 
comorbid diabetes and depression. Outcomes included responses from the Kessler 
Index (K6), six domains of non-specific mental health, and the mental component 
summary (MCS) of the Short-Form 12 (SF-12). Outcomes were estimated using mul-
tivariable regression analyses and adjusted for demographic and clinical charac-
teristics. Results: Compared with adults that had diabetes and no depression (N 
= 4,498), those with diabetes and depression (N = 742) had greater odds of feeling 
nervous all of the time (odds ratio (OR): 2.69; 95% CI: 2.03, 3.56); hopeless all of the 
time (OR: 2.66; 95% CI: 2.02, 3.52; restless all of the time (OR: 2.16; 95% CI: 1.60, 2.93); 
sad all of the time (OR: 1.97; 95% CI: 1.49, 2.61); feeling as though everything is an 
effort all of the time (OR: 2.44; 95% CI: 1.94, 3.09); and feeling worthless all of the 
time (OR: 2.24; 95% CI: 1.77, 2.84). The cohort with diabetes and depression had a 
lower average MCS score of -8.21 (95% CI: -9.26, -7.15) when compared to those with 
diabetes alone. ConClusions: Adults with diabetes and comorbid depression have 
lower self-reported mental health status scores compared to adults with diabetes 
and no depression. Health Care providers should be aware of the additional mental 
health burden depression can have on those with diabetes.
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objeCtives: Hypoglycemia is the major factor limiting intensive glycemic control 
and causing severe morbidity, mortality and reduced quality of life in DM patients. 
Comprehensive assessment of HS is worthwhile. The objective of this study was 
to test applicability and psychometric properties of HS assessment instrument 
– Comprehensive Symptom Profile-Diabetes Mellitus Hypoglycemia Module (CSP-
DM-HypoGl). Methods: 432 DM patients on basal-bolus insulin therapy were 
included in the study: mean age 62±8.4; male/female – 98/334; DM duration – 13±7 
yrs; therapy duration – 5.1±4.3 yrs. Patients filled out CSP-DM-HypoGl and SF-36. 
The CSP-DM-HypoGl was developed to assess the severity of 29 HS in DM patients. 
It consists of numerical rating scales scored from “0” (no symptom) to “10” (most 
expressed symptom). Construct validity of CSP-DM-HypoGl was proved by factor 
analysis, “known-groups” comparison, correlation with SF-36 subscales. Cronbach 
alpha was used to estimate internal consistency. Results: The CSP-DM-HypoGl 
was easily understood by, and administered to patients: the proportion of miss-
ing values was less than 2% for all questions. Practicability of the CSP-DM-HypoGl 
was demonstrated: patients and physicians acknowledged its comprehensiveness. 
Physicians recognized the usefulness of the questionnaire to identify HS and to 
guide treatment strategy. Factor analysis found five underlining constructs for HS 
(explained 61% of the total variance) with Chronbach alphas varied from 0.8 to 0.87. 
“Known-group” comparison revealed that nocturnal problems and neurological HS 
were more pronounced in patients with severe or/and nocturnal hypoglycemia than 
with non-severe hypoglycemia (p< 0.05). Nocturnal problems correlated more closely 
with SF-36 Physical functioning, Vitality and Role Emotional functioning; neurologi-
cal HS – with Vitality and Social functioning (r= 0.3-0.42, p< 0.05). ConClusions: 
The CSP-DM-HypoGl is an appropriate and practical tool for comprehensive assess-
ment of HS in DM patients. Monitoring of HS using CSP-DM-HypoGl may be recom-
mended to enhance treatment benefits in DM patients after testing its sensitivity.
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objeCtives: The prevalence of diabetes mellitus is high among patients with devel-
opmental disabilities (cerebral palsy, autism, down’s syndrome and cognitive dis-
abilities). Developmentally disabled individuals with chronic diseases experience 
delays in detection of comorbidities, poor disease management and low quality 
of care. This study examines the racial health disparities in medication adher-
ence and medication persistence in developmentally disabled adults with type 2 
diabetes enrolled in Medicaid. Methods: This was a retrospective cohort study 
based on a combination of the Health belief model and Aday Anderson’s model 
of health care utilization. The dataset used for this study was the MarketScan® 
Multi-State Medicaid Database. Adults aged 18-64 years with a prior diagnosis of a 
developmental disability (cerebral palsy/autism/down’s/cognitive disabilities) and 
a new diagnosis of type 2 diabetes enrolled in Medicaid from January 1, 2004 and 
December 31, 2006, were included. Adults were included if they had a continuous 
enrollment for at least 12 months and were excluded if they were dual eligible. 
Anti-diabetic medication adherence and diabetic medication persistence were 
measured using multivariate logistic regression and the Cox-proportional hazard 
regression respectively. Results: The study population comprised of 1529 patients. 
After controlling for covariates, African Americans had 24% lower odds of adhering 
to anti-diabetic medications compared to Caucasians. (OR = 0.76, 95% CI = 0.59-0.98, 
p < 0.05). African Americans on the other hand, were more persistent in taking their 
anti-diabetic medications compared to Caucasians. (Hazard Ratio = 0.97, 95% CI = 
